Li and her group employed a novel therapeutic approach involving donor‐derived CD7 CAR‐T therapy followed by allo‐HSCT from the same donor to treat 12 patients with r/r T‐cell acute lymphoblastic leukemia (T‐ALL) or T‐cell lymphoblastic lymphoma (T‐LBL), and 11 patients were alive and disease‐free at their last follow‐up.[48]. Here, CD7 is linked to acute lymphoblastic leukemia.